Pfizer will receive accelerated review in both the U.S. and Europe for its marketing authorization applications for maraviroc. Accelerated reviews are granted to medicines that would potentially represent significant improvements over current therapies. If approved, maraviroc would be the first in a new class of HIV/AIDS treatments called CCR5 antagonists that work by blocking viral entry. Instead of fighting HIV inside white blood cells, CCR5 antagonists prevent the virus produced by infec...